GEM@PLGA@HM were further demonstrated to induce apoptosis of HER2+ tumor cells since the combined therapy intervenes in cell signaling pathways through activation of the apoptosis-related genes such as p53, indicating the strong targeted therapeutic effect of GEM@PLGA@HM on HER2-positive tumors in mice. The gene discussed is TP53; the disease is neoplasm.